



Tetrasodium EDTA Is Effective at Eradicating Biofilms Formed by Clinically Relevant Microorganisms from Patients' Central Venous Catheters

Fangning Liu,^a Satyender Hansra,^a Gordon Crockford,^a Wolfgang Köster,^{a,b} Brenda J. Allan,^a Joseph M. Blondeau,^{c,d,e} Chantal Lainesse,^f  Aaron P. White^{a,e}

^aVaccine and Infectious Disease Organization-International Vaccine Centre, Saskatoon, Saskatchewan, Canada

^bDepartment of Veterinary Microbiology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada

^cDivision of Clinical Microbiology, Royal University Hospital and Saskatoon Health Region, Saskatoon, Saskatchewan, Canada

^dDepartment of Pathology and Ophthalmology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada

^eDepartment of Microbiology and Immunology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada

^fSterileCare, Inc., Markham, Ontario, Canada

ABSTRACT Central venous access devices (CVADs) are an essential component of modern health care. However, their prolonged use commonly results in microbial colonization, which carries the potential risk of hospital-acquired bloodstream infections. These infections complicate the treatment of already sick individuals and cost the existing health care systems around the world millions of dollars. The microbes that colonize CVADs typically form multicellular biofilms that are difficult to dislodge and are resistant to antimicrobial treatments. Clinicians are searching for better ways to extend the working life span of implanted CVADs, by preventing colonization and reducing the risk of bloodstream infections. In this study, we analyzed 210 bacterial and fungal isolates from colonized CVADs or human bloodstream infections from two hospitals geographically separated in the east and west of Canada and screened the isolates for biofilm formation *in vitro*. Twenty isolates, representing 12 common, biofilm-forming species, were exposed to 4% tetrasodium EDTA, an antimicrobial lock solution that was recently approved in Canada for use as a medical device. The EDTA solution was effective at eradicating surface-attached biofilms from each microbial species, indicating that it could likely be used to prevent biofilm growth within CVADs and to eliminate established biofilms. This new lock solution fits with antibiotic stewardship programs worldwide by sparing the use of important antibiotic agents, targeting prevention rather than the expensive treatment of hospital-acquired infections.

IMPORTANCE The colonization of catheters by microorganisms often precludes their long-term use, which can be a problem for human patients that have few body sites available for new catheters. The colonizing organisms often form biofilms, and increasingly these organisms are resistant to multiple antibiotics, making them difficult to treat. In this article, we have taken microorganisms that are associated with biofilm formation in catheters from two Canadian hospitals and tested them with tetrasodium EDTA, a new antimicrobial catheter lock solution. Tetrasodium EDTA was effective at eliminating Gram-positive, Gram-negative, and fungal species and represents a promising alternative to antibiotic treatment with less chance of the organisms developing resistance. We expect that our results will be of interest to researchers and clinicians and will lead to improved patient care.

Received 21 September 2018 **Accepted** 1 November 2018 **Published** 28 November 2018

Citation Liu F, Hansra S, Crockford G, Köster W, Allan BJ, Blondeau JM, Lainesse C, White AP. 2018. Tetrasodium EDTA is effective at eradicating biofilms formed by clinically relevant microorganisms from patients' central venous catheters. *mSphere* 3:e00525-18. <https://doi.org/10.1128/mSphere.00525-18>.

Editor Ana Cristina Gales, Escola Paulista de Medicina/Universidade Federal de São Paulo

Copyright © 2018 Liu et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Aaron P. White, aaron.white@usask.ca.

This article is manuscript no. 851 from VIDO-InterVac.

KEYWORDS EDTA, fungi, Gram-negative, Gram-positive, antibiotic resistance, antimicrobial, biofilms, catheters, central venous access devices, minimum inhibitory concentration

Hospital-acquired infections (HAIs) are often caused by multidrug-resistant bacteria such as methicillin-resistant *Staphylococcus aureus* (MRSA) and *Pseudomonas* (1). HAIs are typically difficult to treat and add complications, such as prolonged hospital stays and death, to an already sick patient (2–4). Incidences of HAI are thought to be underreported due to the use of inefficient medical tracking systems and fear of potential organizational repercussions. One known risk for HAI is the use of central venous access devices (CVADs) (5). At least 70% of all nosocomial bloodstream infections occur in patients who have CVADs (6, 7). This includes patients in intensive care, patients with cancer, and patients who are in need of hemodialysis or total parenteral nutrition (TPN) (8–10).

There is evidence that colonized CVADs can be important carriers of MRSA and other multidrug-resistant bacteria in communities and hospitals worldwide (2, 6). Three processes that can cause CVAD-related complications are clot formation, microbial colonization, and biofilm formation, also known as the TripleThreat (6, 7, 11). It is no longer sufficient to simply prevent clots without providing protection against microorganisms and their associated biofilms (12, 13). Biofilms have a specialized physiology where cells aggregate together and become encased in a self-produced polysaccharide and protein matrix that protects the cells from harsh environmental elements (14–16). Harsh conditions for microorganisms within a CVAD would include mechanical flushing and the use of antibiotic agents (6). Each time the CVAD is used, there is potential for resistant microorganisms sloughing off from a biofilm and entering the patient's bloodstream (6, 11, 17, 18).

Infection control practitioners and catheter management teams worldwide have been aggressively searching for antimicrobial lock solutions to disinfect and keep the inside of the catheters free of microorganisms (7, 19). There is currently no approved lock solution that can effectively protect CVADs against the TripleThreat (12). The current standard of care in many parts of the United States and other areas of the world is heparin or saline (12, 20). Heparin is a well-characterized anticoagulant but has known safety risks, including causing low platelet counts and/or heparin-induced thrombocytopenia; there is also evidence that heparin can stimulate biofilm growth (21). Recently, a 4% tetrasodium ethylenediamine tetraacetic acid (EDTA) lock solution was approved by Health Canada to maintain patency and decrease the risk of bacterial colonization and biofilm formation within CVADs. EDTA has been used for decades as a powerful anticoagulant preventing clot formation *in vitro* (22, 23) and is still being used in this capacity today (24). However, the form of EDTA most often used is the disodium salt, which has reduced antimicrobial properties (25). In contrast, the tetrasodium salt of EDTA has shown the ability to disrupt *in vivo*- and *ex vivo*-generated biofilms (26, 27) and in a randomized, controlled clinical trial showed significant improvement compared to heparin (28).

The most important quality measure for a proposed CVAD treatment is the rate of central-line-associated bloodstream infections (CLABSIs). However, determination of the CLABSI rate suffers from subjectivity and variability, because there is not always a direct link between colonization and known CLABSI events. Not all catheters colonized with bacteria will result in CLABSI, but there is an increase in CLABSI risk when bacteria are detected within catheters (29–31). Rijinders and colleagues established that there is a linear correlation between catheter tip culture (CTC) and CLABSI and that CTC can be used as a surrogate endpoint for CLABSI when catheters are removed (32). It is estimated that a positive bacterial CTC reading has a 20% chance of resulting in a CLABSI event (33–35). Thus, although it is not a perfect measure, investigating the prevention of CTC can be useful for reducing CLABSI prevalence.

The goals in our study were 2-fold: (i) to identify microorganisms isolated by CTC or

from human bloodstream infections and test their biofilm-forming ability and (ii) to evaluate the efficacy of tetrasodium EDTA at eliminating biofilms, toward its use as an antimicrobial lock solution.

RESULTS

Isolation of microorganisms from patients' central venous catheters. As part of a collaborative study with clinicians and nurses at the Southlake Regional Health Center (SRHC) in Ontario (ON), catheters were collected from patients over an 8-month period and cultured for microorganisms using a traditional roll-plate technique coupled with sonication (33–35). A total of 168 isolates were cultured from a total of 305 catheters. This equates to an ~50% isolation and/or colonization rate, since very few catheters had more than one species cultured (data not shown). The isolates obtained belonged to 33 different species, including Gram-negative and Gram-positive bacteria and fungi (Table 1). The most predominant single species was *Staphylococcus epidermidis*, with 66 isolates, which represented 39% of the total. All 11 isolates of *S. aureus* were independently identified to the species level by matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF MS) and confirmed prior to testing for antibiotic resistance. One isolate was identified as MRSA.

In addition to the ON isolates, isolates corresponding to nine different bacterial and fungal species were obtained from patients at the Royal University Hospital, Saskatoon, Saskatchewan (SK) (Table 1). The nine species represented common, biofilm-forming species that have been associated with CVAD colonization (36) and included resistant pathogens such as MRSA and vancomycin-resistant enterococci (VRE). The isolates came from patient specimens submitted for culture and susceptibility testing, but the numbers associated with catheter use are unknown.

Screening isolates for biofilm formation. The 66 *S. epidermidis* isolates from Ontario were screened for biofilm formation in a 96-well plate format by growth in multiple growth media (see Table S1 in the supplemental material). Representative biofilm data are shown for a subset of 25 *S. epidermidis* isolates tested in two established biofilm media (Fig. 1). In this assay, four isolates formed robust biofilms with crystal violet (CV) staining at ≥ 2 to 4 times or > 4 times background (37), and one isolate was chosen for further testing (Fig. 1, arrow). In total, 9 (13.4%) of 66 *S. epidermidis* isolates were identified as moderate to strong biofilm formers.

Similar biofilm screening was performed for each bacterial and fungal species in the ON collection with at least two independent isolates and for all nine bacterial and fungal species originating from the SK collection. The goal was to identify one or more isolates from each species that formed robust and reproducible biofilms that could be further tested. For each species, we identified at least one strong biofilm-forming isolate, with the exception of *Ralstonia insidiosa* (data not shown). The antimicrobial resistance patterns were determined for each of these biofilm-forming isolates (see Table S2 in the supplemental material).

Determination of MIC, MBC, and MBEC values for tetrasodium EDTA. For the strong biofilm-forming isolates identified, we tested the MIC and minimum bactericidal concentration (MBC) for tetrasodium EDTA, when the isolates were grown as single cells in liquid culture. Representative data are shown for ON *S. epidermidis* and MRSA isolates (Fig. 2). Both isolates had no visible signs of growth in the presence of 0.063% tetrasodium EDTA as measured by optical density (OD) (Fig. 2A and D), whereas complete killing was achieved at 0.5% and 1.0% tetrasodium EDTA, respectively (Fig. 2B and E). To test the resistance of isolates when grown as biofilms, minimum biofilm eradication concentration (MBEC) assays were performed after growth of organisms on the surface of polystyrene pegs. MBEC values of 1.0% and 0.5% (Fig. 2C and F), which were similar to the MBC values, were obtained for both strains.

The MIC, MBC, and MBEC values for tetrasodium EDTA were determined for one or more isolates from each selected species originating from the ON and SK hospitals (Table 2). In general, MBC values were higher than the corresponding MIC tests, indicating that tetrasodium EDTA was not bactericidal at lower concentrations. Gram-

TABLE 1 Bacterial and fungal isolates cultured from central venous access devices or human blood samples

Organism type	No. of isolates	% of total
Ontario (CVADs) ^a		
Gram-positive bacteria	120	71.4
<i>Staphylococcus epidermidis</i>	66	39.3
<i>Staphylococcus aureus</i>	11 ^b	6.5
Other <i>Staphylococcus</i> spp. ^c	20	11.9
<i>Bacillus</i> spp. ^d	9	5.4
<i>Corynebacterium</i> spp. ^e	5	3.0
<i>Enterococcus faecalis</i>	2	1.2
Other Gram-positive species ^f	7	4.2
Gram-negative bacteria	34	20.2
<i>Ralstonia insidiosa</i>	6	3.6
<i>Stenotrophomonas maltophilia</i>	5	3.0
<i>Enterobacter agglomerans</i>	4	2.4
<i>Proteus mirabilis</i>	3	1.8
<i>Escherichia coli</i>	2	1.2
Other Gram-negative spp. ^g	14	8.3
Fungi	14	8.3
<i>Candida albicans</i>	10	6.0
<i>Candida glabrata</i>	4	2.4
Ontario total	168	
Saskatchewan (blood samples) ^h		
Gram-positive bacteria	15	NA ⁱ
<i>Staphylococcus epidermidis</i>	12	
MRSA	3	
VRE ^j	3	
Gram-negative bacteria	12	NA
<i>Pseudomonas aeruginosa</i>	3	
<i>Klebsiella pneumoniae</i>	3	
<i>Serratia marcescens</i>	3	
<i>Escherichia coli</i>	3	
Fungi	15	NA
<i>Candida albicans</i>	12	
<i>Candida glabrata</i>	3	
Saskatchewan total	42	

^aIsolates from Ontario were cultured from 305 catheter tips removed from patients at Southlake Regional Health Centre.

^bOne *S. aureus* isolate was classified as methicillin resistant (MRSA).

^cAdditional *Staphylococcus* species included *S. lugdunensis* (7 isolates), *S. hominis* (6 isolates), *S. simulans* (2 isolates), *S. capitis* (2 isolates), and undetermined (3 isolates).

^d*Bacillus* species included *B. licheniformis* (2 isolates), *B. megaterium* (2 isolates), *B. simplex* (1 isolate), *B. cereus* group (1 isolate), and undetermined (3 isolates).

^e*Corynebacterium* species included *C. tuberculostearicum* (2 isolates) and undetermined, not *C. jeikeium* (3 isolates).

^fAdditional Gram-positive species included *Streptococcus mitis* (1 isolate), *Nocardia* spp. (1 isolate), *Paenibacillus* spp. (1 isolate), and undetermined (4 isolates).

^gAdditional Gram-negative species included *Comamonas testosteroni* (3 isolates), *Sphingomonas paucimobilis* (3 isolates), *Brevundimonas* spp. (2 isolates), *Pseudomonas oryzyhabitans* (2 isolates), *Ralstonia pickettii* (1 isolate), *Roseomonas gilardii* (1 isolate), *Rothia* spp. (1 isolate), and undetermined (1 isolate).

^hIsolates from Saskatchewan were cultured from patient blood samples from Royal University Hospital in Saskatoon.

^jVRE, vancomycin-resistant *Enterococcus faecalis*.

ⁱNA, not applicable.

negative bacteria and *Candida* isolates were more resistant, with MIC and MBC values that were, on average, 2 to 3 dilutions higher than those of the Gram-positive bacterial isolates. The concentration of tetrasodium EDTA required for killing biofilm cells was 4% for 8 of 20 tested isolates, whereas the remaining 12 isolates had MBEC values below 4% (Table 2).

The clinically accepted standard of killing of microorganisms by an antimicrobial agent is at least a 3-log reduction in cell numbers (38). To visualize this standardized level of killing, the MBEC data from each experiment were plotted as the log reduction in the number of colony-forming units (see Fig. S1 in the supplemental material). For




FIG 1 Biofilm screening of *S. epidermidis* isolates. Twenty-five *S. epidermidis* isolates originating from central venous access devices were inoculated into 96-well plates and grown for 24 h at 37°C in biofilm media: M9, M9 minimal media; CAA, Casamino Acids; TSB, tryptic soy broth. Biofilm cell mass in each well was quantitated by crystal violet staining and measuring the absorbance of the resulting solution at 590 nm (A_{590}). Bars represent the average values and error bars the standard deviations from 6 biological replicates. The dashed horizontal line represents the average A_{590} value from uninoculated control wells. Stars denote isolates that were judged to have robust biofilm formation. Isolate 170 (arrow) was chosen for subsequent testing.

13 of 20 tested isolates, greater than 4-log killing was achieved (Table 2). For the remaining 7 isolates, the starting biofilm cell densities were not high enough to achieve a 4-log reduction. However, in each case, 4% tetrasodium EDTA was able to kill biofilm cells down to the limit of detection for the assay (Fig. S1).

Exposure time required to kill *in vitro*-formed biofilms. The exposure time for MBEC assays was set to 24 h to follow established guidelines (39). However, there are several clinical scenarios in which catheter lock solutions could be used for less than 24 h. To establish the minimum contact time necessary for complete biofilm killing to occur, we tested each selected biofilm-forming isolate by exposure to 4% tetrasodium EDTA for 1, 3, 6, or 24 h (Fig. 3). In these time-to-kill assays, tetrasodium EDTA was directly compared to a water control, which accounts for cells that may slough off the pegs in a passive manner compared to cells that are actively killed.

All Gram-positive isolates showed a statistically significant drop in CFU compared to controls after 6 h of exposure (Fig. 3A). The *S. epidermidis* isolate from Ontario was completely killed after 3 h, whereas the three *S. aureus* isolates required longer exposure times to drop CFU values near the limit of detection, and a full 24 h was required for complete killing. For *Enterococcus faecalis*, although biofilm formation for both ON and SK isolates was not as robust as that of the other Gram-positive species, complete killing was achieved within 6 h. The results with Gram-negative bacteria were quite different. All 8 isolates had killing at or near the limit of detection within 3 h of exposure, and none required a full 24 h of exposure (Fig. 3B). Six of eight Gram-negative isolates had complete killing achieved by 6 h. Finally, *Candida* species appeared to be the most resistant to tetrasodium EDTA, as each selected isolate required a full 24 h of exposure for complete killing to occur (Fig. 3C).

DISCUSSION

There is currently a great need for the development of effective nonantibiotic antimicrobials that can be used in a clinical setting. Antibiotic resistance of microorganisms is a huge problem and is anticipated to increase in severity with time (40, 41).




FIG 2 Determination of MIC, MBC, and MBEC values of tetrasodium EDTA against *Staphylococcus* isolates cultured from central venous access devices. Individual isolates of *S. epidermidis* (A, B, and C) and methicillin-resistant *S. aureus* (D, E, and F) were tested in MIC (A and D), MBC (B and E), and MBEC (C and F) assays. Horizontal bars represent the mean OD₆₀₀ or viable bacterial cell (CFU/ml) values after cultures were exposed to increasing amounts of tetrasodium EDTA. Arrows represent MIC, MBC, and MBEC values. The dashed horizontal lines on each graph represent the background OD₆₀₀ values in uninoculated control wells (A and D) or the CFU limit of detection (B, C, E, and F). Three biological replicate cultures were tested in duplicate or triplicate for each type of assay; each dot represents one replicate.

In this study, we tested the ability of 4% tetrasodium EDTA to kill clinically significant bacterial and fungal pathogens isolated from two Canadian hospitals. The tetrasodium EDTA solution was able to kill all microorganisms tested, at a concentration of 4% or less, and in less than 24 h of exposure. We also tested organisms when grown as biofilms, which represents a worst-case scenario for the colonization of catheters (6, 7) and contributes to numerous clinical diseases (42, 43). As anticipated, biofilms were the most difficult physiology to eradicate; however, clinically significant levels of killing were achieved (i.e., 4-log reduction in CFU or 99.99% killing) for 13 of 20 isolates tested. For the remaining seven isolates, the initial biofilm density was not as high, so even though cells were killed at or below detectable levels, 4-log killing could not be achieved. These results indicated that 4% tetrasodium EDTA was an effective antimicrobial agent against all tested Gram-positive and Gram-negative bacteria and fungi coming from patients.

Microbial colonization of CVADs is known to be a major contributing factor to CLABSI, HAI, and the spread of antibiotic resistance (6, 19, 44). In our study, the 54% rate of bacterial and fungal isolate identification from 305 catheters was similar to what has been reported before (33). The Maki roll technique, which has low sensitivity for isolation of intraluminal bacteria (34), was combined with sonication to maximize the chances of detecting bacterial colonization. Recently, culture-independent approaches have shown that both “symptomatic” and “nonsymptomatic” catheters contain diverse microorganisms (45–47), with “symptomatic” catheters colonized at higher levels and the most numerically dominant organisms often being the only ones cultured. This could explain the commonly held dogma that some catheters are colonized and others

TABLE 2 Effectiveness of tetrasodium EDTA at killing clinically relevant microorganisms grown as single cells or as biofilms

Organism type ^a	Result (%) by:			Biofilm killing ^b
	MIC	MBC	MBEC	
Gram-positive bacteria				
<i>Staphylococcus epidermidis</i>				
ON	0.063	0.5	1.0	4.2
SK	0.063	0.5	2.0	3.7
<i>Staphylococcus aureus</i>				
ON	0.063	1.0 ^c	4.0	6.0
Methicillin resistant				
ON	0.063	1.0	0.5	4.6
SK	0.063	2.0 ^c	4.0	4.4
<i>Enterococcus faecalis</i>				
ON	0.063	2.0	4.0	3.7
Vancomycin resistant (SK)	0.031	2.0	0.25	1.8
Gram-negative bacteria				
<i>Escherichia coli</i>				
ON	0.5	1.0	1.0	5.6
SK	0.125	0.25	2.0	4.4
<i>Stenotrophomonas maltophilia</i> (ON)	0.063	1.0	4.0	6.5
<i>Pseudomonas aeruginosa</i> (SK)	0.25	1.0	4.0	5.3
<i>Enterobacter agglomerans</i> (ON)	0.125	0.25	4.0	5.1
<i>Serratia marcescens</i> (SK)	1.0	1.0	4.0	5.0
<i>Proteus mirabilis</i> (ON)	0.063	2.0	4.0	5.7
<i>Klebsiella pneumoniae</i> (SK)	1.0	1.0	2.0	4.6
Fungi				
<i>Candida albicans</i>				
ON	1.0	2.0	1.0	2.7
SK	1.0	1.0	1.0	1.7
<i>Candida glabrata</i>				
ON	0.25	2.0	1.0	1.9
SK	0.125	2.0	1.0	2.0
Control bacteria				
<i>Salmonella enterica</i> serovar Typhimurium	0.25	0.5	1.0	4.7

^aMicroorganisms were obtained from Southlake Regional Health Centre in Ontario (ON) and Royal University Hospital in Saskatchewan (SK).

^bThese numbers refer to the log₁₀ reductions of differences between the mean starting number of cells in the biofilm and the mean number of remaining cells after treatment with tetrasodium EDTA for 24 h at the concentrations listed in the MBEC column.

^cMBC was determined by confirming the lack of surviving cells through inoculation of the treated culture into fresh medium and growth for 24 h at 37°C.

are not. In our study, the isolated organisms likely represent a mix of attached, surface- or lumen-associated cells (33, 34). We obtained diverse Gram-negative, Gram-positive, and fungal isolates, and *S. epidermidis* was the most predominant single species, which matches well with previous reports (36, 45, 47). However, if we had employed a culture-independent approach focused on sequencing, we anticipate that microorganisms would have been detected in nearly 100% of the catheters.

More research is needed to better understand what signals trigger biofilm development in the host and to learn how to extrapolate these signals to the *in vitro* environment. Although it is difficult to know the true prevalence of *in vivo* biofilm formation, recent studies using microscopic examination of the inside of catheters indicate that it could be near 100% (45–47). Despite this high *in vivo* prevalence, only 10 to 15% of isolates in our study were capable of forming robust biofilms *in vitro*. This was particularly surprising for *S. epidermidis*, which is the number 1 species associated with catheter biofilms *in vivo* in Canada (36) and in other areas in the world (48, 49). We hypothesize that the inability of most isolates to make biofilms *in vitro* is due to the difficulty in reproducing *in vivo* conditions. In light of recent sequencing results, it is possible that most or all catheter biofilms are multispecies, which could mean that




FIG 3 Minimum exposure time to kill bacterial/fungal biofilms with 4% tetrasodium EDTA. *In vitro* biofilms formed by Gram-positive bacteria (A), Gram-negative bacteria (B), fungal species (C), and control bacteria (D) were formed on polystyrene pegs prior to testing. For each graph, the hatched bar (0 h) shows the starting CFU/ml values measured from control pegs ($n = 8$). Formed biofilms were exposed to 4% tetrasodium EDTA (black bars) or water [125 CFU/ml] (gray bars) for the times shown; four biological replicates with four technical replicates ($n = 16$) were analyzed for treatment groups, along with four biological replicates with two technical replicates ($n = 8$) for water controls. Bars represent the average CFU/ml detected, and error bars represent the standard deviation. The time points where biofilms were killed near or at the limit of detection (dotted line [125 CFU/ml]) are highlighted in yellow. Values from each treatment group were compared to the corresponding water controls by unpaired *t* tests with Welch's correction. Statistical significance is noted above each treatment bar: ns, not significant ($P > 0.05$); *, $P < 0.05$. Arrows denote the minimum exposure times required for complete eradication of the bacterial/fungal biofilms.




FIG 3 (Continued)

microorganisms need to interact for efficient attachment to occur and to foster the development of a mature biofilm matrix (43, 44, 50, 51). Perhaps the stepwise addition of organisms is required, as has been observed for microbial biofilms formed on human teeth (52). There is also a strong possibility that microbial cells are in a different metabolic state *in vivo* due to the presence of blood and trace elements, as well as oxygen and nutrient gradients (53, 54). Many of these factors are difficult to control in




FIG 3 (Continued)

the laboratory setting, but each could play a role in stimulating microbial attachment (55, 56). As we have done here, researchers often characterize biofilm-forming “type” strains and make the assumption that they are representative of the entire species. It should also be noted that quantitation of *in vitro* biofilms is inherently flawed, since crystal violet staining is an indirect measurement of biomass that suffers from a lack of reproducibility, and sonication only removes a proportion of bound cells from the polystyrene pegs of MBEC devices.

Treatment of monoculture biofilms with tetrasodium EDTA revealed different susceptibilities, depending on the class of organism. Gram-negative isolates were killed in the shortest exposure time but generally required higher concentrations of tetrasodium EDTA, presumably to overcome the stringent outer and inner membrane barriers (57). In contrast, Gram-positive isolates took longer to kill but were killed at lower concentrations. We are not sure why this difference was detected, but it could reflect a difference in biofilm architecture compared to Gram-negative organisms. Perhaps lack of an outer membrane in Gram-positive bacteria renders them susceptible to lower concentrations of EDTA. *Candida* species, which can exist in both cellular and hyphal forms (58–60), were the most difficult to treat, requiring the highest concentrations and

exposure times. The fact that tetrasodium EDTA worked against all three classes of organisms confirms that it has wide-ranging antimicrobial effects. The majority of effects are assumed to be due to its chelation activity, including outer membrane damage and changes to chromosomal and RNA activity (61–64). With EDTA predicted to have more generalized mechanism of killing, we hypothesize that it would be difficult for microorganisms to develop resistance. EDTA can also increase the permeability of microbial membranes (62, 65), suggesting that it could be used synergistically with other antimicrobial compounds or with low levels of antibiotics that have fallen out of use. The increased access to cellular targets afforded by EDTA would also be predicted to decrease the rates of resistance.

The use of antimicrobial lock solutions is becoming increasingly attractive to clinicians to extend the life span of CVADs and improve patient health (12). In critically ill patients or patients with long-term catheter use, if lines become blocked, there can sometimes be a lack of other suitable sites of entry (7). The antimicrobial killing effects shown in this study indicate that tetrasodium EDTA used as a catheter lock solution would reduce the chance of bacteria getting flushed into the body. In addition, repeated exposure of microorganisms to such a lock solution would be predicted to have a cumulative effect. Exposure times may often be increased from what we have tested here (i.e., hemodialysis patients for 24 to 72 h [17], oncology patients for 24 h to 3 weeks [8], and total parenteral nutrition patients for 12 to 24 h [66]).

Based on 2011 data from the World Health Organization and the U.S. Centers for Disease Control, the overall rates of infections acquired in hospital are 4.5% in the United States, 7.1% in Europe, and 11.6% in Canada (1). Published data indicate that each year in Canada, there are 50,000 catheter-associated bloodstream infections with approximately 12,500 related deaths and an estimated \$1.2 billion dollars of health care expenditure to treat these infections. The use of a nonantibiotic, antimicrobial lock solution, like 4% tetrasodium EDTA, for preventative maintenance of catheters in patients fits well with antibiotic stewardship programs currently mandated around the world. This treatment would help to reduce the rates of CLABSI and other complications that are associated with long-term CVAD use.

MATERIALS AND METHODS

Isolation and identification of microorganisms from patient samples. During an 8-month period at the Southlake Regional Health Centre in Newmarket, Ontario, 305 CVADs were collected from patients >18 years old. A 1-ml sample of the lock fluid was taken, CVADs were aseptically removed from patients, and the last distal 10 cm of the catheter was placed into a sterile collection tube. Sample collection and processing were done in compliance with protocols approved by the SRHC's Research Ethics Board.

Catheter tip and lock solution samples were processed for microbiological culture in the laboratory of Tony Mazzulli (Mt. Sinai Hospital, Department of Microbiology, Toronto, ON). Following the methodology of Guembe and colleagues (34), each tip was rolled on a blood agar plate to detect extraluminal microorganisms (i.e., the Maki roll technique) and then cut into pieces into 5-ml brain heart infusion (BHI) medium followed by sonication to dislodge intraluminal microorganisms. After 1 min of sonication, a 0.1-ml aliquot of solution was removed and inoculated onto blood agar. The BHI/catheter tip solution was sonicated for an additional 4 min, and a 0.1-ml aliquot was removed and inoculated onto blood agar. For the lock solutions, the entire 1-ml sample was inoculated onto two blood agar plates. All blood agar plates were incubated at 35°C in 5% CO₂ atmosphere for 24 or 48 h, and the total number of colonies of each type of isolate was recorded. For species identification, isolates were streak purified on blood agar plates and identified using the Vitek-MS automated mass spectrometry microbial identification system (bioMérieux). Susceptibility testing was performed following standard procedures with breakpoints recommended by the Clinical and Laboratory Standards Institute (CLSI). Glycerol stocks of each isolate were sent to VIDO-InterVac (Saskatoon, Saskatchewan [SK]) and used for all subsequent experiments.

Saskatchewan isolates were collected through the clinical microbiology laboratory at Royal University Hospital (Saskatoon, SK) from patient specimens that were submitted for culture and susceptibility testing. Organism identification was by matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF). Initial antimicrobial susceptibility testing was performed with a Vitek II instrument using the GPS 67 card. For MRSA, organisms screening as resistant to oxacillin and ceftoxitin were further tested for altered penicillin-binding protein (PBP) production using a latex agglutination assay. Confirmation using a PCR assay for the *mecA* gene was used if the susceptibility results and PBP assay did not agree. VRE isolates were confirmed for vancomycin resistance using Etest strips (bioMérieux). From blood agar, all isolates were inoculated into brain heart infusion (BHI) broth and grown for 18 h at 37°C, and freezer stocks were prepared in 20% glycerol.

Conditions for routine growth of microorganisms. Gram-positive and Gram-negative bacterial isolates were cultivated in Mueller-Hinton (MH) or Mueller-Hinton II (MH II) broth (Becton, Dickinson). *Candida albicans* and *Candida glabrata* isolates were grown in 1% tryptone broth supplemented with 0.5% glucose. Prior to each MIC, MBC, and MBEC experiment, isolates were inoculated from frozen stocks onto MH II agar and incubated at 37°C for 16 to 40 h. Individual colonies were used to inoculate 5 ml of the appropriate medium, and the culture was incubated at 37°C for 16 to 18 h with shaking at 200 rpm. These cultures were diluted to the desired cell concentrations and used for inoculation into 96-well plates.

Determining the relationship between optical density and cell number for each microorganism. To determine the conversion factor for cell number as a function of optical density for each strain, 1-ml stock cultures were prepared from overnight cultures to an optical density at 600 nm (OD_{600}) of 1.0, and the cell number was determined by serial dilution and plating. The “drop dilution assay” consists of a 10-fold dilution series prepared in duplicate in a 96-well plate and 4- μ l drops of the 10^{-1} to 10^{-6} dilutions inoculated in duplicate onto agar plates. After incubation at 37°C for 16 to 18 h, colonies were counted and recorded at the appropriate dilution that yielded between 3 and 30 colonies.

Biofilm screening of microbial isolates. Bacterial and fungal broth cultures were diluted to deliver 10^7 cells (Gram-positive and Gram-negative species) or 10^5 cells (*Candida* species) into wells of non-tissue-culture-treated, polystyrene 96-well plates (Falcon no. 351172). Growth was tested in a variety of media (Table S1) at 150 μ l per well at 28 or 37°C for 24 or 48 h; inoculated plates were covered with lids, sealed with Parafilm, and incubated with slight rocking on a tilting platform shaker. Each isolate was tested with 6 to 8 replicates. Biofilm cell mass was quantitated by crystal violet (CV) staining (67). The 96-well plates were washed twice by being submerged into a water tray, followed by being shaken into a waste tray to remove nonattached cells. After air drying for 10 min, 125 μ l of 0.1% (wt/vol) crystal violet solution was added to each well, and the plate was incubated for 10 to 15 min at room temperature. After staining, plates were washed twice with water and vigorously tapped on paper towels to remove any excess liquid, followed by air drying for 5 to 10 min. Two hundred microliters of 95% ethanol was added to each well, and the plates were covered and incubated for 15 min at room temperature. One hundred twenty-five microliters of solution from each well was transferred into a new clear flat-bottom 96-well plate (Greiner Bio One, no. 655101), and the optical density at 590 nm was measured. The best biofilm-forming isolates, as determined by CV staining, were further tested to determine the optimal conditions to facilitate maximum biofilm formation (Table 3). For *Candida* species, the biofilm growth conditions outlined by Serrano-Fujarte et al. (68) were used as a starting point.

Tetrasodium EDTA solution. KiteLock 4% sterile catheter lock solution was supplied in 3-ml polypropylene ampoules (SterileCare, Inc.; Markham, ON, Canada). The patented solution is maintained at a high pH and contains 40 mg ml^{-1} of tetrasodium ethylenediamine tetraacetic acid (EDTA). We confirmed that a high pH was maintained for the tested range of dilutions used in all MIC, MBC, and MBEC assays (see Fig. S2 in the supplemental material).

MIC and MBC assays with tetrasodium EDTA. MIC assays were performed using the broth microdilution method in 96-well plates, as recommended by the Clinical and Laboratory Standards Institute (CLSI [69]). In each assay, three biological replicates of one selected isolate were tested with 2 to 3 technical replicates. Tetrasodium EDTA was serially diluted 2-fold in the wells so that the final concentration ranged from 2% to 0.004%, and each well contained 50% growth medium, in a final volume of 100 μ l. Wells were inoculated with 10^5 bacterial cells or 2×10^3 fungal cells, which are levels recommended by CLSI. Inoculated and uninoculated wells containing 100% growth medium were included as controls in each assay. The inoculated 96-well plates were covered with lids, sealed with Parafilm, and incubated at 37°C for 24 h with slight rocking on tilting platform shaker. The optical density of the cultures in each well was measured at 600 nm using a Victor X3 multilabel plate reader (Perkin Elmer). The MIC value was identified as the concentration breakpoint at which culture OD_{600} values were similar to those of uninoculated control wells. The MBC value was determined from the MIC plates by enumerating the viable bacterial cells in each well by drop dilution assay. MBC values were determined as the concentration resulting in CFU/ml values at the limit of detection (LOD [62.5 CFU ml^{-1}]).

MBEC assays with tetrasodium EDTA. MBEC biofilm inoculator plates (Innovotech, AB, Canada), consisting of a 96-well plate bottom and a plastic lid with 96 polystyrene pegs attached, were used to grow biofilms, following procedures outlined by Harrison et al. (39). A total of 1.5×10^5 (bacteria), 5×10^5 (*C. albicans*), or 3×10^6 (*C. glabrata*) cells were inoculated into wells containing the appropriate biofilm test medium (Table 3) to reach a final volume of 150 μ l. For each isolate, two biological replicate cultures were tested in triplicate. The plates were sealed with Parafilm and incubated at 28 or 37°C for 24 or 48 h, with slight rocking for bacteria or orbital shaking at 200 rpm for fungal isolates. After biofilm growth, the pegs were washed twice in phosphate-buffered saline (PBS) for 2 min. Pegs in column 1 ($n = 6$) represented biofilm growth controls; after washing, these pegs were removed and analyzed as described below to determine the starting biofilm cell numbers.

For antimicrobial challenge, the pegs were placed into a new 96-well plate containing 200 μ l of tetrasodium EDTA ranging from a final concentration of 4% to 0.008% in 50% growth medium. The last column of wells did not contain EDTA, and these pegs were used as the untreated control. The plate was sealed with Parafilm and incubated at 37°C for 24 h, with slight rocking on a platform shaker. After the challenge, the pegs attached to the lid were washed twice in PBS for 2 min and transferred to a 96-well plate containing 200 μ l of recovery medium (growth medium supplemented with 1% Tween 80) in each well. The recovery plate was sealed with Parafilm, placed in a metal tray inside a Branson 3510 bath sonicator (Branson, Canada), and sonicated for 30 min. After sonication, drop dilution assays were performed to enumerate the viable cells dislodged from the pegs. MBEC values were determined as the

TABLE 3 Optimal *in vitro* growth conditions for biofilm formation of microorganisms isolated from two Canadian hospitals

Organism type ^a	Biofilm medium ^b	Incubation conditions ^c
Gram-positive bacteria		
<i>S. epidermidis</i>		
ON	MH II + 2% NaCl	48 h at 37°C
SK	M9 + 0.5% glucose, 0.5% CAA	24 h at 37°C
<i>S. aureus</i>		
ON	TSB + 1.5% glucose	24 h at 37°C
Methicillin resistant		
ON	BHI + 2% glucose, 4% NaCl	48 h at 37°C
SK	BHI + 1% glucose, 4% NaCl	24 h at 37°C
<i>E. faecalis</i>		
ON	TSB/BHI + 1% glucose, 4% NaCl	48 h at 37°C
Vancomycin resistant (SK)	TSB + 2% glucose, 4% NaCl	48 h at 37°C
Gram-negative bacteria		
<i>Escherichia coli</i>		
ON	M9 + 0.2% glucose, 0.2% CAA	48 h at 28°C
SK	M63 + 0.3% glucose, 0.5% CAA	48 h at 28°C
<i>Stenotrophomonas maltophilia</i> (ON)	TSB + 0.5% glucose	48 h at 37°C
<i>Pseudomonas aeruginosa</i> (SK)	LB	24 h at 37°C
<i>Enterobacter agglomerans</i> (ON)	M9 + 0.1% glucose, 1.0% CAA	48 h at 28°C
<i>Serratia marcescens</i> (SK)	TSB	48 h at 28°C
<i>Proteus mirabilis</i> (ON)	M63 + 0.25% glucose, 0.5% CAA	24 h at 37°C
<i>Klebsiella pneumoniae</i> (SK)	M9 + 0.25% glucose, 0.5% CAA	24 h at 37°C
Fungi		
<i>Candida albicans</i> (ON or SK)	YPD/2% glucose	24 h at 37°C
<i>Candida glabrata</i> (ON or SK)	YNB	48 h at 28°C
Control bacteria		
<i>Salmonella enterica</i> serovar Typhimurium	1/2 LB no salt + 40 μ M 2,2-dipyridyl	24 h at 37°C

^aMicroorganisms were obtained from the Southlake Regional Health Centre in Ontario (ON) or the Royal University Hospital in Saskatchewan (SK).

^bMH II, Mueller-Hinton II broth; M9, M9 minimal medium; CAA, Casamino Acids; TSB, tryptic soy broth; BHI, brain heart infusion; M63, M63 minimal medium; LB, lysogeny broth; YPD/2% glucose, 1% yeast extract and 2% peptone supplemented with 2% glucose; YNB, yeast nitrogen base.

^cFor bacterial isolates, slight rocking was applied during growth; for fungal isolates, orbital shaking at 200 rpm was applied, which improved overall biofilm formation.

concentration of tetrasodium EDTA that yielded a viable cell concentration at or near the LOD (125 CFU ml⁻¹) for at least 50% of the biological and technical replicates. As a final test of killing, the lid with pegs was transferred into a plate containing 150 μ l of growth medium per well, and cells were grown overnight. In each case where a value is reported at the LOD, there was no growth detected after 24 h.

Control bacteria for MIC, MBC, and MBEC assays. To ensure consistency and reproducibility from plate to plate for the MIC, MBC, and MBEC assays, two rows were inoculated with *Salmonella enterica* serovar Typhimurium ATCC 14028. In one row, tetrasodium EDTA was used at the same concentrations as the rest of the plate, and in the second row, gentamicin was used, ranging from a concentration of 400 μ g ml⁻¹ to 0.8 μ g ml⁻¹.

Exposure time to eradicate biofilms (time-to-kill assays). Bacterial and fungal biofilms were grown as described for the MBEC assays. After growth, control pegs ($n = 16$) were removed and analyzed to determine the starting biofilm cell numbers. After washing twice in PBS to remove growth medium, the biofilm pegs were exposed to 200 μ l of 4% tetrasodium EDTA or sterile water (control) and incubated at 37°C for 1, 3, 6, or 24 h. Four biological replicates of each isolate were tested, with four technical replicates analyzed for 4% tetrasodium EDTA treatment and 2 technical replicates analyzed for water controls. After each exposure time, the biofilm cells were dislodged from the pegs by sonication, and viable cells were enumerated by drop dilution. Killing time was defined as the shortest exposure time that resulted in numbers of viable cells at or near the LOD (125 CFU ml⁻¹) for at least 50% of the biological and technical replicates.

Statistical analysis. Statistical analysis of the data was performed using GraphPad Prism version 7.0c. For MBEC assays, the log reduction values (CFU/ml) at each test concentration were logarithmically transformed and evaluated using the Shapiro-Wilk normality test, which determined that the data were not normally distributed. A Kruskal-Wallis test was utilized to compare the differences between the log reductions at each test concentration and the appropriate medium control. For time-to-kill assays, unpaired *t* tests with Welch's correction were used to compare CFU/ml values from 4% tetrasodium EDTA and water control treatments. For the Kruskal-Wallis and *t* tests, a *P* value of <0.05 was considered to be statistically significant.

SUPPLEMENTAL MATERIAL

Supplemental material for this article may be found at <https://doi.org/10.1128/mSphere.00525-18>.

FIG S1, PDF file, 0.6 MB.

FIG S2, TIF file, 0.2 MB.

TABLE S1, PDF file, 0.1 MB.

TABLE S2, PDF file, 0.1 MB.

ACKNOWLEDGMENTS

We are grateful to the nurses and clinicians at the Southlake Regional Health Centre and Royal University Hospital for collection of patient samples, to members of the Glassware and Media Preparation team at VIDO-InterVac, and to Melissa Palmer and Akosierem Sokaribo for laboratory assistance.

Chantal Laines reports a financial interest in the subject matter but has collaborated in an editorial fashion and only provided background information with no influence on results, interpretation of results, or conclusions.

This work was funded by the Natural Sciences and Engineering Research Council of Canada (NSERC), through Engage (EGP 500938-16), Engage Plus (EGP2 515729-16), and Discovery (DG 05737-2017) grants to A.P.W. The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

W.L.K., B.J.A., F.L., and A.P.W. conceived and designed the experiments. F.L., S.H., G.C., B.J.A., and A.P.W. performed the experiments. F.L., S.H., W.L.K., B.J.A., J.M.B., and A.P.W. analyzed the data. J.M.B. and C.L. contributed reagents, materials, or analysis tools. F.L., W.L.K., B.J.A., J.M.B., C.L., and A.P.W. wrote the manuscript.

REFERENCES

- World Health Organization 2011. Report on the burden of endemic health care-associated infection worldwide. World Health Organization, Geneva, Switzerland. www.who.int/gpsc/country_work/burden_hcai/en/.
- O'Grady NP, Alexander M, Burns LA, Dellinger EP, Garland J, Heard SO, Lipsitt PA, Masur H, Mermel LA, Pearson ML, Raad II, Randolph AG, Rupp ME, Saint S, Healthcare Infection Control Practices Advisory Committee (HICPAC). 2011. Guidelines for the prevention of intravascular catheter-related infections. *Clin Infect Dis* 52:e162–e193. <https://doi.org/10.1093/cid/cir257>.
- Murphy D, Whiting J. 2007. Dispelling the myths: the true cost of healthcare-associated infections. Association for Professionals in Infection Control and Epidemiology (APIC), Washington, DC.
- Little MA, O'Riordan A, Lucey B, Farrell M, Lee M, Conlon PJ, Walshe JJ. 2001. A prospective study of complications associated with cuffed, tunnelled haemodialysis catheters. *Nephrol Dial Transplant* 16: 2194–2200. <https://doi.org/10.1093/ndt/16.11.2194>.
- Chopra V, O'Horo JC, Rogers MAM, Maki DG, Safdar N. 2013. The risk of bloodstream infection associated with peripherally inserted central catheters compared with central venous catheters in adults: a systematic review and meta-analysis. *Infect Control Hosp Epidemiol* 34:908–918. <https://doi.org/10.1086/671737>.
- Ryder MA. 2005. Catheter-related infections: it's all about biofilm. *Top Adv Pract Nursing* 5. <https://www.medscape.com/viewarticle/508109>.
- Gominet M, Compain F, Beloin C, Lebeaux D. 2017. Central venous catheters and biofilms: where do we stand in 2017? *APMIS* 125:365–375. <https://doi.org/10.1111/apm.12665>.
- Schiffer CA, Mangu PB, Wade JC, Camp-Sorrell D, Cope DG, El-Rayes BF, Gorman M, Ligibel J, Mansfield P, Levine M. 2013. Central venous catheter care for the patient with cancer: American Society of Clinical Oncology clinical practice guideline. *J Clin Oncol* 31:1357–1370. <https://doi.org/10.1200/JCO.2012.45.5733>.
- Zhang L, Sriprakash KS, McMillan D, Gowardman JR, Patel B, Rickard CM. 2010. Microbiological pattern of arterial catheters in the intensive care unit. *BMC Microbiol* 10:266. <https://doi.org/10.1186/1471-2180-10-266>.
- Lai C-H, Wong W-W, Chin C, Huang C-K, Lin H-H, Chen W-F, Yu K-W, Liu C-Y. 2006. Central venous catheter-related *Stenotrophomonas maltophilia* bacteraemia and associated relapsing bacteraemia in haematology and oncology patients. *Clin Microbiol Infect* 12:986–991. <https://doi.org/10.1111/j.1469-0691.2006.01511.x>.
- Goossens GA. 2015. Flushing and locking of venous catheters: available evidence and evidence deficit. *Nurs Res Pract* 2015:985686. <https://doi.org/10.1155/2015/985686>.
- Bleyer AJ, Murea M. 2011. Antimicrobial catheter locks: searching for the ideal solution. *J Am Soc Nephrol* 22:1781–1782. <https://doi.org/10.1681/ASN.2011080839>.
- Donlan RM. 2011. Biofilm elimination on intravascular catheters: important considerations for the infectious disease practitioner. *Clin Infect Dis* 52:1038–1045. <https://doi.org/10.1093/cid/cir077>.
- Kostaki M, Chorianopoulos N, Braxou E, Nychas G-J, Giaouris E. 2012. Differential biofilm formation and chemical disinfection resistance of sessile cells of *Listeria monocytogenes* strains under monospecies and dual-species (with *Salmonella enterica*) conditions. *Appl Environ Microbiol* 78:2586–2595. <https://doi.org/10.1128/AEM.07099-11>.
- Fey PD, Olson ME. 2010. Current concepts in biofilm formation of *Staphylococcus epidermidis*. *Future Microbiol* 5:917–933. <https://doi.org/10.2217/fmb.10.56>.
- Flemming H-C, Wingender J, Szewzyk U, Steinberg P, Rice SA, Kjelleberg S. 2016. Biofilms: an emergent form of bacterial life. *Nat Rev Microbiol* 14:563–575. <https://doi.org/10.1038/nrmicro.2016.94>.
- Mermel LA. 2014. What is the evidence for intraluminal colonization of hemodialysis catheters? *Kidney Int* 86:28–33. <https://doi.org/10.1038/ki.2013.527>.
- Kong EF, Tsui C, Kucharíková S, Andes D, Van Dijk P, Jabra-Rizk MA. 2016. Commensal protection of *Staphylococcus aureus* against antimicrobials by *Candida albicans* biofilm matrix. *mBio* 7:e01365-16. <https://doi.org/10.1128/mBio.01365-16>.
- Lebeaux D, Ghigo J-M, Beloin C. 2014. Biofilm-related infections: bridging the gap between clinical management and fundamental aspects of recalcitrance toward antibiotics. *Microbiol Mol Biol Rev* 78:510–543. <https://doi.org/10.1128/MMBR.00013-14>.
- Hadaway L. 2006. Heparin locking for central venous catheters. *J Assoc Vasc Access* 11:224–231. <https://doi.org/10.2309/java.11-4-17>.
- Shanks RMQ, Donegan NP, Graber ML, Buckingham SE, Zegans ME, Cheung AL, O'Toole GA. 2005. Heparin stimulates *Staphylococcus aureus*

- biofilm formation. *Infect Immun* 73:4596–4606. <https://doi.org/10.1128/IAI.73.8.4596-4606.2005>.
22. Proescher F. 1951. Anti-coagulant properties of ethylene bisiminodiacetic acid. *Proc Soc Exp Biol Med* 76:619–620. <https://doi.org/10.3181/00379727-76-18577>.
 23. Lam NYL, Rainer TH, Chiu RWK, Lo YMD. 2004. EDTA is a better anticoagulant than heparin or citrate for delayed blood processing for plasma DNA analysis. *Clin Chem* 50:256–257. <https://doi.org/10.1373/clinchem.2003.026013>.
 24. Chandra J, Long L, Isham N, Mukherjee PK, DiSciullo G, Appelt K, Ghannoum MA. 2018. In vitro and in vivo activity of a novel catheter lock solution against bacterial and fungal biofilms. *Antimicrob Agents Chemother* 62:e00722-18. <https://doi.org/10.1128/AAC.00722-18>.
 25. Hogan S, Zapotoczna M, Stevens NT, Humphreys H, O'Gara JP, O'Neill E. 2016. In vitro approach for identification of the most effective agents for antimicrobial lock therapy in the treatment of intravascular catheter-related infections caused by *Staphylococcus aureus*. *Antimicrob Agents Chemother* 60:2923–2931. <https://doi.org/10.1128/AAC.02885-15>.
 26. Kite P, Eastwood K, Sugden S, Percival SL. 2004. Use of in vivo-generated biofilms from hemodialysis catheters to test the efficacy of a novel antimicrobial catheter lock for biofilm eradication in vitro. *J Clin Microbiol* 42:3073–3076. <https://doi.org/10.1128/JCM.42.7.3073-3076.2004>.
 27. Percival SL, Kite P, Eastwood K, Murga R, Carr J, Arduino MJ, Donlan RM. 2005. Tetrasodium EDTA as a novel central venous catheter lock solution against biofilm. *Infect Control Hosp Epidemiol* 26:515–519. <https://doi.org/10.1086/502577>.
 28. Kanaa M, Wright MJ, Akbani H, Laboi P, Bhandari S, Sandoe JAT. 2015. Cathasept line lock and microbial colonization of tunneled hemodialysis catheters: a multicenter randomized controlled trial. *Am J Kidney Dis* 66:1015–1023. <https://doi.org/10.1053/j.ajkd.2015.04.047>.
 29. Yousif A, Jamal MA, Raad I. 2015. Biofilm-based central line-associated bloodstream infections. *Adv Exp Med Biol* 830:157–179. https://doi.org/10.1007/978-3-319-11038-7_10.
 30. Kaur M, Gupta V, Gombar S, Chander J, Sahoo T. 2015. Incidence, risk factors, microbiology of venous catheter associated bloodstream infections—a prospective study from a tertiary care hospital. *Indian J Med Microbiol* 33:248–254. <https://doi.org/10.4103/0255-0857.153572>.
 31. Strasheim W, Kock MM, Ueckermann V, Hoosien E, Dreyer AW, Ehlers MM. 2015. Surveillance of catheter-related infections: the supplementary role of the microbiology laboratory. *BMC Infect Dis* 15:5. <https://doi.org/10.1186/s12879-014-0743-5>.
 32. Rijnders BJA, Van Wijngaerden E, Peetermans WE. 2002. Catheter-tip colonization as a surrogate end point in clinical studies on catheter-related bloodstream infection: how strong is the evidence? *Clin Infect Dis* 35:1053–1058. <https://doi.org/10.1086/342905>.
 33. Sherertz RJ, Heard SO, Raad II. 1997. Diagnosis of triple-lumen catheter infection: comparison of roll plate, sonication, and flushing methodologies. *J Clin Microbiol* 35:641–646.
 34. Guembe M, Martín-Rabadán P, Cruces R, Pérez Granda MJ, Bouza E. 2016. Sonicating multi-lumen sliced catheter tips after the roll-plate technique improves the detection of catheter colonization in adults. *J Microbiol Methods* 122:20–22. <https://doi.org/10.1016/j.mimet.2016.01.004>.
 35. Guembe M, Marín M, Martín-Rabadán P, Echenagusia A, Camúñez F, Rodríguez-Rosales G, Simó G, Echenagusia M, Bouza E, GEIDI Study Group. 2013. Use of universal 16S rRNA gene PCR as a diagnostic tool for venous access port-related bloodstream infections. *J Clin Microbiol* 51:799–804. <https://doi.org/10.1128/JCM.02414-12>.
 36. Public Health Agency of Canada. 2014. Central venous catheter-associated blood stream infections in intensive care units in Canadian acute-care hospitals: surveillance report January 1, 2006 to December 31, 2006 and January 1, 2009 to December 31, 2011. Public Health Agency of Canada, Ottawa, Ontario, Canada.
 37. Stepanovic S, Vukovic D, Dakic I, Savic B, Svabic-Vlahovic M. 2000. A modified microtiter-plate test for quantification of staphylococcal biofilm formation. *J Microbiol Methods* 40:175–179. [https://doi.org/10.1016/S0167-7012\(00\)00122-6](https://doi.org/10.1016/S0167-7012(00)00122-6).
 38. Pankey GA, Sabath LD. 2004. Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections. *Clin Infect Dis* 38:864–870. <https://doi.org/10.1086/381972>.
 39. Harrison JJ, Stremick CA, Turner RJ, Allan ND, Olson ME, Ceri H. 2010. Microtiter susceptibility testing of microbes growing on peg lids: a miniaturized biofilm model for high-throughput screening. *Nat Protoc* 5:1236–1254. <https://doi.org/10.1038/nprot.2010.71>.
 40. Holmes AH, Moore LSP, Sundsfjord A, Steinbakk M, Regmi S, Karkey A, Guerin PJ, Piddock LJV. 2016. Understanding the mechanisms and drivers of antimicrobial resistance. *Lancet* 387:176–187. [https://doi.org/10.1016/S0140-6736\(15\)00473-0](https://doi.org/10.1016/S0140-6736(15)00473-0).
 41. Review on Antimicrobial Resistance 2016. Tackling drug-resistant infections globally: final report and recommendations. O'Neill J (ed), Review on Antimicrobial Resistance, London, United Kingdom. https://amr-revision.org/sites/default/files/160518_Final%20paper_with%20cover.pdf.
 42. Costerton JW, Stewart PS, Greenberg EP. 1999. Bacterial biofilms: a common cause of persistent infections. *Science* 284:1318–1322. <https://doi.org/10.1126/science.284.5418.1318>.
 43. Uppuluri P, Lopez-Ribot JL. 2016. Go forth and colonize: dispersal from clinically important microbial biofilms. *PLoS Pathog* 12:e1005397. <https://doi.org/10.1371/journal.ppat.1005397>.
 44. Harriott MM, Noverr MC. 2009. *Candida albicans* and *Staphylococcus aureus* form polymicrobial biofilms: effects on antimicrobial resistance. *Antimicrob Agents Chemother* 53:3914–3922. <https://doi.org/10.1128/AAC.00657-09>.
 45. Stressmann FA, Couve-Deacon E, Chainier D, Chauhan A, Wessel A, Durand-Fontanier S, Escande M-C, Kriegel I, Francois B, Ploy M-C, Beloin C, Ghigo J-M. 2017. Comparative analysis of bacterial community composition and structure in clinically symptomatic and asymptomatic central venous catheters. *mSphere* 2:e00146-17. <https://doi.org/10.1128/mSphere.00146-17>.
 46. Kanaa M, Wright MJ, Sandoe JAT. 2010. Examination of tunnelled haemodialysis catheters using scanning electron microscopy. *Clin Microbiol Infect* 16:780–786. <https://doi.org/10.1111/j.1469-0691.2009.02952.x>.
 47. Zhang L, Gowardman J, Morrison M, Krause L, Playford EG, Rickard CM. 2014. Molecular investigation of bacterial communities on intravascular catheters: no longer just *Staphylococcus*. *Eur J Clin Microbiol Infect Dis* 33:1189–1198. <https://doi.org/10.1007/s10096-014-2058-2>.
 48. Cherifi S, Byl B, Deplano A, Nonhoff C, Denis O, Hallin M. 2013. Comparative epidemiology of *Staphylococcus epidermidis* isolates from patients with catheter-related bacteremia and from healthy volunteers. *J Clin Microbiol* 51:1541–1547. <https://doi.org/10.1128/JCM.03378-12>.
 49. Widerström M, Wiström J, Sjöstedt A, Monsen T. 2012. Coagulase-negative staphylococci: update on the molecular epidemiology and clinical presentation, with a focus on *Staphylococcus epidermidis* and *Staphylococcus saprophyticus*. *Eur J Clin Microbiol Infect Dis* 31:7–20. <https://doi.org/10.1007/s10096-011-1270-6>.
 50. Wolcott R, Costerton JW, Raoult D, Cutler SJ. 2013. The polymicrobial nature of biofilm infection. *Clin Microbiol Infect* 19:107–112. <https://doi.org/10.1111/j.1469-0691.2012.04001.x>.
 51. Cowan MM, Warren TM, Fletcher M. 1991. Mixed-species colonization of solid surfaces in laboratory biofilms. *Biofouling* 3:23–34. <https://doi.org/10.1080/08927019109378159>.
 52. Kolenbrander PE, Palmer RJ, Periasamy S, Jakubovics NS. 2010. Oral multispecies biofilm development and the key role of cell-cell distance. *Nat Rev Microbiol* 8:471–480. <https://doi.org/10.1038/nrmicro2381>.
 53. Albenberg L, Esipova TV, Judge CP, Bittinger K, Chen J, Laughlin A, Grunberg S, Baldassano RN, Lewis JD, Li H, Thom SR, Bushman FD, Vinogradov SA, Wu GD. 2014. Correlation between intraluminal oxygen gradient and radial partitioning of intestinal microbiota. *Gastroenterology* 147:1055–1063.e8. <https://doi.org/10.1053/j.gastro.2014.07.020>.
 54. Fuchs TM, Eisenreich W, Heesemann J, Goebel W. 2012. Metabolic adaptation of human pathogenic and related nonpathogenic bacteria to extra- and intracellular habitats. *FEMS Microbiol Rev* 36:435–462. <https://doi.org/10.1111/j.1574-6976.2011.00301.x>.
 55. Wessel AK, Arshad TA, Fitzpatrick M, Connell JL, Bonnacaze RT, Shear JB, Whiteley M. 2014. Oxygen limitation within a bacterial aggregate. *mBio* 5:e00992. <https://doi.org/10.1128/mBio.00992-14>.
 56. Yawata Y, Nguyen J, Stocker R, Rusconi R. 2016. Microfluidic studies of biofilm formation in dynamic environments. *J Bacteriol* 198:2589–2595. <https://doi.org/10.1128/JB.00118-16>.
 57. Blair JMA, Webber MA, Baylay AJ, Ogbolu DO, Piddock LJV. 2015. Molecular mechanisms of antibiotic resistance. *Nat Rev Microbiol* 13:42–51. <https://doi.org/10.1038/nrmicro3380>.
 58. Brunke S, Hube B. 2013. Two unlike cousins: *Candida albicans* and *C. glabrata* infection strategies. *Cell Microbiol* 15:701–708. <https://doi.org/10.1111/cmi.12091>.
 59. Taff HT, Mitchell KF, Edward JA, Andes DR. 2013. Mechanisms of *Candida* biofilm drug resistance. *Future Microbiol* 8:1325–1337. <https://doi.org/10.2217/fmb.13.101>.

60. Lu Y, Su C, Unoje O, Liu H. 2014. Quorum sensing controls hyphal initiation in *Candida albicans* through Ubr1-mediated protein degradation. *Proc Natl Acad Sci U S A* 111:1975–1980. <https://doi.org/10.1073/pnas.1318690111>.
61. Gray GW, Wilkinson SG. 1965. The action of ethylenediaminetetra-acetic acid on *Pseudomonas aeruginosa*. *J Appl Microbiol* 28:153–164. <https://doi.org/10.1111/j.1365-2672.1965.tb04547.x>.
62. Vaara M. 1992. Agents that increase the permeability of the outer membrane. *Microbiol Rev* 56:395–411.
63. Chang Y, Gu W, McLandsborough L. 2012. Low concentration of ethylenediaminetetraacetic acid (EDTA) affects biofilm formation of *Listeria monocytogenes* by inhibiting its initial adherence. *Food Microbiol* 29: 10–17. <https://doi.org/10.1016/j.fm.2011.07.009>.
64. Geesey GG, Wigglesworth-Cooksey B, Cooksey KE. 2000. Influence of calcium and other cations on surface adhesion of bacteria and diatoms: a review. *Biofouling* 15:195–205. <https://doi.org/10.1080/08927010009386310>.
65. Leive L. 1965. A nonspecific increase in permeability in *Escherichia coli* produced by EDTA. *Proc Natl Acad Sci U S A* 53:745–750. <https://doi.org/10.1073/pnas.53.4.745>.
66. Spires SS, Rebeiro PF, Miller M, Koss K, Wright PW, Talbot TR. 2018. Medically attended catheter complications are common in patients with outpatient central venous catheters. *Infect Control Hosp Epidemiol* 39: 439–444. <https://doi.org/10.1017/ice.2018.8>.
67. Merritt JH, Kadouri DE, O'Toole GA. 2005. Growing and analyzing static biofilms. *Curr Protoc Microbiol* Chapter 1:Unit 1B.1. <https://doi.org/10.1002/9780471729259.mc01b01s00>.
68. Serrano-Fujarte I, López-Romero E, Reyna-López GE, Martínez-Gómez MA, Vega-González A, Cuéllar-Cruz M. 2015. Influence of culture media on biofilm formation by *Candida* species and response of sessile cells to antifungals and oxidative stress. *BioMed Res Int* 2015:1–15. <https://doi.org/10.1155/2015/783639>.
69. CLSI. 2017. Performance standards for antimicrobial susceptibility testing; 23rd informational supplement. CLSI document M100-S27. CLSI, Wayne, PA.